More Than Skin Deep: A new partnership to ease the hidden burden of Eczema in the UAE
In response to this growing healthcare challenge, Jamjoom Pharma and the Emirates Dermatology Society (EDS) have signed today a Memorandum of Understanding (MoU) to launch ' ECZPLORE' —a pioneering awareness campaign aimed at changing the way eczema is understood, managed, and supported in the UAE.
'Eczema is not just a rash—it's a chronic disease that affects the entire family,' said Dr. Ayman Al Naeem, President of the Emirates Dermatology Society. 'We believe that early education and empathetic support can change the daily reality for children living with eczema. Recent studies suggest that 1 in 5 children in the UAE suffer from eczema, with over half of moderate-to-severe cases remaining uncontrolled. The condition not only disrupts sleep and school life, but also doubles the likelihood of anxiety and depression in caregivers, highlighting the urgent need for broader public awareness.'
The ECZPLORE program will roll out nationwide through schools, clinics, and digital channels. It includes child-friendly materials like coloring books and storybooks, adult-focused guides and magazines, and tailored support for healthcare professionals —all designed to help families better understand the condition and how to lead an 'eczema-friendly' life.
'At Jamjoom Pharma, our purpose is to serve patient well-being through knowledge, care, and community support,' said Dr. Samer Lezzaiq, General Manager - Gulf, Levant & Export Markets at Jamjoom Pharma. 'Through ECZPLORE, we aim to break the silence around eczema, equip caregivers with real tools, and give children the confidence to live without shame.'
The partnership also extends into fungal infection awareness, targeting both patients and professionals with actionable educational campaigns.
Together, Jamjoom Pharma and EDS hope to drive a cultural shift in how chronic skin conditions are perceived and managed, transforming frustration into understanding—and silence into support.
About Jamjoom Pharmaceuticals:
Jamjoom Pharma is a leading pharmaceutical organization committed to enhancing the quality of life through the development, manufacturing, and distribution of high-quality medicines and consumer healthcare products. Headquartered in Saudi Arabia, the company was established back in 2000 and is tirelessly operating to support the Saudi Vision 2030 to reinforce the public healthcare system.
With a strong focus on research, innovation, and patient-centered care, Jamjoom Pharma serves diverse markets across Middle East & Africa, with a bold ambition to expand globally, providing effective solutions in key therapeutic areas (including ophthalmology, dermatology, cardiometabolic, gastrointestinal, and general medicine).
Through its state-of-the-art facilities across the MEA region and dedication to regulatory excellence, Jamjoom Pharma continues to deliver products that meet the highest standards of safety, efficacy, and quality, improving health outcomes for millions of people.
Jamjoom Pharma Media Contact:
Vivian Fikry, Corporate Communications Director
M: +201222701256
E: Vivian.fikry@jamjoompharma.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Zawya
12 hours ago
- Zawya
Egypt: EFG Hermes advises on $190mln DPI investment in Alameda
Arab Finance: EFG Hermes, the investment banking arm of EFG Holding, has announced its role as sole M&A financial advisor on a $190 million minority stake investment in Egypt's Alameda Healthcare by Development Partners International (DPI), as per an emailed press release. This was in partnership with a consortium of institutional investors and development finance institutions. The deal, one of the largest foreign direct investments in Egypt's healthcare sector, involves a capital increase and is expected to close in the third quarter (Q3) of 2025, pending regulatory approvals. Fahad Khater will remain the majority shareholder of Alameda following the transaction. The investment is set to boost Alameda's growth across Egypt and the GCC, with proceeds entering the local banking system to support the expansion of hospital operations and clinical capacity in key regional markets. This marks one of several major transactions led by EFG Hermes this year, reinforcing its leadership in M&A, DCM, and ECM advisory across Egypt, the UAE, Saudi Arabia, and Oman. © 2020-2023 Arab Finance For Information Technology. All Rights Reserved. Provided by SyndiGate Media Inc. (
Zawya
14 hours ago
- Zawya
Gulf Medical University announces second cycle of Thumbay International Research Grant of AED3mln to fuel innovation and impact -25/26
In a bold step to propel global medical research and healthcare innovation, Thumbay Group—through its academic flagship Gulf Medical University (GMU)—has launched the Second Cycle of the Thumbay International Research Grant 2025/26. With a total allocation of AED 3 million, the grant reaffirms Thumbay Group's commitment to empowering research that transforms lives, strengthens healthcare systems, and addresses real-world challenges. This initiative invites visionary researchers from around the world to submit proposals that are rooted in innovation, evidence-based methodology, and interdisciplinary collaboration. The focus areas include some of the most critical frontiers in healthcare: precision oncology, drug discovery, AI applications in medicine, public health, healthcare systems and health economics, veterinary medicine, and innovation in medical education. The grant serves as a powerful platform that connects scientific discovery with societal progress. It is designed to nurture research that delivers tangible outcomes in patient care, medical education, and the integration of technology in healthcare systems. At its core lies a belief in the transformative power of ideas. Through this initiative, we are investing in visionary minds and trailblazers whose work will shape the future of medicine and spark the next generation of breakthroughs. Commenting on the announcement, Dr. Thumbay Moideen, Founder President of Thumbay Group, said, 'Through this grant, we are investing to make Gulf Medical University a leading research-based university and United Arab Emirates to be a Hub for research and innovation. In the next two years, we hope to increase the Grant amount to AED 10 Million.' Echoing the founder's vision, Prof. Manda Venkatramana, Acting Chancellor at GMU, added, 'Our goal is to create an ecosystem where research is not confined to the lab but extended into clinics and communities, making an impact on patient outcomes. With over 100 leading industry partners, GMU is proud to serve as the launchpad for innovation with purpose.' Proposals are now being accepted, with a submission deadline of November 30, 2025. This initiative by Thumbay Group once again places the UAE at the heart of global efforts to foster cutting-edge research, proving that when visionary leadership meets purpose-driven science, the possibilities are limitless. Gulf Medical University is one of the region's leading academic health centers, known for its innovation-driven medical education and global collaborations. With over 90 nationalities represented on campus and partnerships with more than 60 universities worldwide, GMU is committed to shaping future healthcare leaders.
Zawya
14 hours ago
- Zawya
More Than Skin Deep: A new partnership to ease the hidden burden of Eczema in the UAE
Abu Dhabi, Eczema, often dismissed as 'just a skin problem,' affects far more than the skin. For thousands of children in the UAE - and the families who care for them - it's a relentless battle of itching, poor sleep, emotional distress, and social isolation. Parents stay up through the night tending to their children's wounds, while children miss school, avoid friendships, and battle anxiety at a young age. This invisible epidemic is robbing too many families of comfort, confidence, and peace of mind. In response to this growing healthcare challenge, Jamjoom Pharma and the Emirates Dermatology Society (EDS) have signed today a Memorandum of Understanding (MoU) to launch ' ECZPLORE' —a pioneering awareness campaign aimed at changing the way eczema is understood, managed, and supported in the UAE. 'Eczema is not just a rash—it's a chronic disease that affects the entire family,' said Dr. Ayman Al Naeem, President of the Emirates Dermatology Society. 'We believe that early education and empathetic support can change the daily reality for children living with eczema. Recent studies suggest that 1 in 5 children in the UAE suffer from eczema, with over half of moderate-to-severe cases remaining uncontrolled. The condition not only disrupts sleep and school life, but also doubles the likelihood of anxiety and depression in caregivers, highlighting the urgent need for broader public awareness.' The ECZPLORE program will roll out nationwide through schools, clinics, and digital channels. It includes child-friendly materials like coloring books and storybooks, adult-focused guides and magazines, and tailored support for healthcare professionals —all designed to help families better understand the condition and how to lead an 'eczema-friendly' life. 'At Jamjoom Pharma, our purpose is to serve patient well-being through knowledge, care, and community support,' said Dr. Samer Lezzaiq, General Manager - Gulf, Levant & Export Markets at Jamjoom Pharma. 'Through ECZPLORE, we aim to break the silence around eczema, equip caregivers with real tools, and give children the confidence to live without shame.' The partnership also extends into fungal infection awareness, targeting both patients and professionals with actionable educational campaigns. Together, Jamjoom Pharma and EDS hope to drive a cultural shift in how chronic skin conditions are perceived and managed, transforming frustration into understanding—and silence into support. About Jamjoom Pharmaceuticals: Jamjoom Pharma is a leading pharmaceutical organization committed to enhancing the quality of life through the development, manufacturing, and distribution of high-quality medicines and consumer healthcare products. Headquartered in Saudi Arabia, the company was established back in 2000 and is tirelessly operating to support the Saudi Vision 2030 to reinforce the public healthcare system. With a strong focus on research, innovation, and patient-centered care, Jamjoom Pharma serves diverse markets across Middle East & Africa, with a bold ambition to expand globally, providing effective solutions in key therapeutic areas (including ophthalmology, dermatology, cardiometabolic, gastrointestinal, and general medicine). Through its state-of-the-art facilities across the MEA region and dedication to regulatory excellence, Jamjoom Pharma continues to deliver products that meet the highest standards of safety, efficacy, and quality, improving health outcomes for millions of people. Jamjoom Pharma Media Contact: Vivian Fikry, Corporate Communications Director M: +201222701256 E:
